As further evidence supporting the use of the Mv-HER3 candidate in resistant scenarios, the passive transfer of the PAbs generated by immunization with the HER3-based candidate to mice bearing human DU145 tumors inhibited tumor growth compared to control mice. This evidence concerns the gene ERBB3 and neoplasm.